Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2011

Open Access 01-12-2011 | Original investigation

Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men

Authors: Weena JY Chen, Luuk J Rijzewijk, Rutger W van der Meer, Martijn W Heymans, Eelco van Duinkerken, Mark Lubberink, Adriaan A Lammertsma, Hildo J Lamb, Albert de Roos, Johannes A Romijn, Jan WA Smit, Jeroen J Bax, Mette Bjerre, Jan Frystyk, Allan Flyvbjerg, Michaela Diamant

Published in: Cardiovascular Diabetology | Issue 1/2011

Login to get access

Abstract

Background

Osteoprotegerin (OPG), a soluble member of the tumor necrosis factor receptor superfamily, is linked to cardiovascular disease. Negative associations exist between circulating OPG and cardiac function. The adipocytokine adiponectin (ADPN) is downregulated in type 2 diabetes mellitus (T2DM) and coronary artery disease and shows an inverse correlation with insulin sensitivity and cardiovascular disease risk. We assessed the relationship of plasma OPG and ADPN and arterial function, cardiac function and myocardial glucose metabolism in T2DM.

Methods

We included 78 asymptomatic men with uncomplicated, well-controlled T2DM, without inducible ischemia, assessed by dobutamine-stress echocardiography, and 14 age-matched controls. Cardiac function was measured by magnetic resonance imaging, myocardial glucose metabolism (MMRglu) by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography. OPG and ADPN levels were measured in plasma.

Results

T2DM patients vs. controls showed lower aortic distensibility, left ventricular (LV) volumes, impaired LV diastolic function and MMRglu (all P < 0.05). In T2DM men vs. controls, OPG levels were higher (P = 0.02), whereas ADPN concentrations were decreased (P = 0.04). OPG correlated inversely with aortic distensibility, LV volumes and E/A ratio (diastolic function), and positively with LV mass/volume ratio (all P < 0.05). Regression analyses showed the associations with aortic distensibility and LV mass/volume ratio to be independent of age-, blood pressure- and glycated hemoglobin (HbA1c). However, the associations with LV volumes and E/A ratio were dependent of these parameters. ADPN correlated positively with MMRglu (P < 0.05), which, in multiple regression analysis, was dependent of whole-body insulin sensitivity, HbA1c and waist.

Conclusions

OPG was inversely associated with aortic distensibility, LV volumes and LV diastolic function, while ADPN was positively associated with MMRglu. These findings indicate that in asymptomatic men with uncomplicated T2DM, OPG and ADPN may be markers of underlying mechanisms linking the diabetic state to cardiac abnormalities.

Trial registration

Current Controlled Trials ISRCTN53177482
Appendix
Available only for authorised users
Literature
1.
go back to reference Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.CrossRefPubMed Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.CrossRefPubMed
2.
go back to reference Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de RA, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M: Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009, 54: 1524-1532. 10.1016/j.jacc.2009.04.074.CrossRefPubMed Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de RA, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M: Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009, 54: 1524-1532. 10.1016/j.jacc.2009.04.074.CrossRefPubMed
3.
go back to reference Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de RA, Radder JK: Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003, 42: 328-335. 10.1016/S0735-1097(03)00625-9.CrossRefPubMed Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de RA, Radder JK: Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003, 42: 328-335. 10.1016/S0735-1097(03)00625-9.CrossRefPubMed
4.
go back to reference Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.CrossRefPubMed Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.CrossRefPubMed
5.
go back to reference Schoppet M, Preissner KT, Hofbauer LC: RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002, 22: 549-553. 10.1161/01.ATV.0000012303.37971.DA.CrossRefPubMed Schoppet M, Preissner KT, Hofbauer LC: RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002, 22: 549-553. 10.1161/01.ATV.0000012303.37971.DA.CrossRefPubMed
6.
go back to reference Flyvbjerg A: Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol. 2010, 6: 94-101. 10.1038/nrendo.2009.266.CrossRefPubMed Flyvbjerg A: Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol. 2010, 6: 94-101. 10.1038/nrendo.2009.266.CrossRefPubMed
7.
go back to reference Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA: Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007, 49: 1392-1398. 10.1161/HYPERTENSIONAHA.107.087742.CrossRefPubMed Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA: Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007, 49: 1392-1398. 10.1161/HYPERTENSIONAHA.107.087742.CrossRefPubMed
8.
go back to reference Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P: Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005, 111: 2461-2468. 10.1161/01.CIR.0000165119.62099.14.CrossRefPubMed Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P: Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005, 111: 2461-2468. 10.1161/01.CIR.0000165119.62099.14.CrossRefPubMed
9.
go back to reference Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y: Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost. 2010, 8: 1170-1175. 10.1111/j.1538-7836.2010.03833.x.CrossRefPubMed Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y: Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost. 2010, 8: 1170-1175. 10.1111/j.1538-7836.2010.03833.x.CrossRefPubMed
10.
go back to reference Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006, 47: 1850-1857. 10.1016/j.jacc.2005.12.054.CrossRefPubMed Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006, 47: 1850-1857. 10.1016/j.jacc.2005.12.054.CrossRefPubMed
11.
go back to reference Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P: Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care. 2010, 33: 2561-2566. 10.2337/dc10-0858.PubMedCentralCrossRefPubMed Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P: Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care. 2010, 33: 2561-2566. 10.2337/dc10-0858.PubMedCentralCrossRefPubMed
12.
go back to reference Chandran M, Phillips SA, Ciaraldi T, Henry RR: Adiponectin: more than just another fat cell hormone?. Diabetes Care. 2003, 26: 2442-2450. 10.2337/diacare.26.8.2442.CrossRefPubMed Chandran M, Phillips SA, Ciaraldi T, Henry RR: Adiponectin: more than just another fat cell hormone?. Diabetes Care. 2003, 26: 2442-2450. 10.2337/diacare.26.8.2442.CrossRefPubMed
13.
go back to reference Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001, 86: 1930-1935. 10.1210/jc.86.5.1930.CrossRefPubMed Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001, 86: 1930-1935. 10.1210/jc.86.5.1930.CrossRefPubMed
14.
go back to reference Tuttolomondo A, La PS, Di RD, Bellia C, Caruso A, Lo SB, Guercio G, Diana G, Ciaccio M, Licata G, Pinto A: Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol. 2010, 9: 50-10.1186/1475-2840-9-50.PubMedCentralCrossRefPubMed Tuttolomondo A, La PS, Di RD, Bellia C, Caruso A, Lo SB, Guercio G, Diana G, Ciaccio M, Licata G, Pinto A: Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol. 2010, 9: 50-10.1186/1475-2840-9-50.PubMedCentralCrossRefPubMed
15.
go back to reference Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB: Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005, 54: 534-539.CrossRefPubMed Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB: Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005, 54: 534-539.CrossRefPubMed
16.
go back to reference Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de RA, Lamb HJ: Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008, 52: 1793-1799. 10.1016/j.jacc.2008.07.062.CrossRefPubMed Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de RA, Lamb HJ: Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008, 52: 1793-1799. 10.1016/j.jacc.2008.07.062.CrossRefPubMed
17.
go back to reference van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de RA, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M: Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009, 119: 2069-2077. 10.1161/CIRCULATIONAHA.108.803916.CrossRefPubMed van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de RA, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M: Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009, 119: 2069-2077. 10.1161/CIRCULATIONAHA.108.803916.CrossRefPubMed
18.
go back to reference Ewing DJ, Martyn CN, Young RJ, Clarke BF: The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985, 8: 491-498. 10.2337/diacare.8.5.491.CrossRefPubMed Ewing DJ, Martyn CN, Young RJ, Clarke BF: The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985, 8: 491-498. 10.2337/diacare.8.5.491.CrossRefPubMed
19.
go back to reference van der Meer RW, Diamant M, Westenberg JJ, Doornbos J, Bax JJ, de RA, Lamb HJ: Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson. 2007, 9: 645-651. 10.1080/10976640601093703.CrossRefPubMed van der Meer RW, Diamant M, Westenberg JJ, Doornbos J, Bax JJ, de RA, Lamb HJ: Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson. 2007, 9: 645-651. 10.1080/10976640601093703.CrossRefPubMed
20.
go back to reference Resnick LM, Militianu D, Cunnings AJ, Pipe JG, Evelhoch JL, Soulen RL: Direct magnetic resonance determination of aortic distensibility in essential hypertension: relation to age, abdominal visceral fat, and in situ intracellular free magnesium. Hypertension. 1997, 30: 654-659.CrossRefPubMed Resnick LM, Militianu D, Cunnings AJ, Pipe JG, Evelhoch JL, Soulen RL: Direct magnetic resonance determination of aortic distensibility in essential hypertension: relation to age, abdominal visceral fat, and in situ intracellular free magnesium. Hypertension. 1997, 30: 654-659.CrossRefPubMed
21.
go back to reference Paelinck BP, de RA, Bax JJ, Bosmans JM, van Der Geest RJ, Dhondt D, Parizel PM, Vrints CJ, Lamb HJ: Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J Am Coll Cardiol. 2005, 45: 1109-1116. 10.1016/j.jacc.2004.12.051.CrossRefPubMed Paelinck BP, de RA, Bax JJ, Bosmans JM, van Der Geest RJ, Dhondt D, Parizel PM, Vrints CJ, Lamb HJ: Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J Am Coll Cardiol. 2005, 45: 1109-1116. 10.1016/j.jacc.2004.12.051.CrossRefPubMed
22.
go back to reference DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237: E214-E223.PubMed DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237: E214-E223.PubMed
23.
go back to reference Knaapen P, Boellaard R, Gotte MJ, Dijkmans PA, van Campen LM, de Cock CC, Luurtsema G, Visser CA, Lammertsma AA, Visser FC: Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy. J Nucl Med. 2004, 45: 1299-1304.PubMed Knaapen P, Boellaard R, Gotte MJ, Dijkmans PA, van Campen LM, de Cock CC, Luurtsema G, Visser CA, Lammertsma AA, Visser FC: Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy. J Nucl Med. 2004, 45: 1299-1304.PubMed
24.
go back to reference Hermansen F, Rosen SD, Fath-Ordoubadi F, Kooner JS, Clark JC, Camici PG, Lammertsma AA: Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols. Eur J Nucl Med. 1998, 25: 751-759. 10.1007/s002590050279.CrossRefPubMed Hermansen F, Rosen SD, Fath-Ordoubadi F, Kooner JS, Clark JC, Camici PG, Lammertsma AA: Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols. Eur J Nucl Med. 1998, 25: 751-759. 10.1007/s002590050279.CrossRefPubMed
25.
go back to reference Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985, 5: 584-590. 10.1038/jcbfm.1985.87.CrossRefPubMed Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985, 5: 584-590. 10.1038/jcbfm.1985.87.CrossRefPubMed
26.
go back to reference Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A: Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 2006, 154: 75-81. 10.1530/eje.1.02049.CrossRefPubMed Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A: Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 2006, 154: 75-81. 10.1530/eje.1.02049.CrossRefPubMed
27.
go back to reference Andersen KK, Frystyk J, Wolthers OD, Heuck C, Flyvbjerg A: Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab. 2007, 92: 1857-1862. 10.1210/jc.2006-2310.CrossRefPubMed Andersen KK, Frystyk J, Wolthers OD, Heuck C, Flyvbjerg A: Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab. 2007, 92: 1857-1862. 10.1210/jc.2006-2310.CrossRefPubMed
28.
go back to reference Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM: Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005, 28: 2176-2180. 10.2337/diacare.28.9.2176.CrossRefPubMed Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM: Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005, 28: 2176-2180. 10.2337/diacare.28.9.2176.CrossRefPubMed
29.
go back to reference Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP, Dupuy AM: Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007, 30: 2934-2939. 10.2337/dc07-0992.CrossRefPubMed Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP, Dupuy AM: Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007, 30: 2934-2939. 10.2337/dc07-0992.CrossRefPubMed
30.
go back to reference Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB: Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost. 2011, 9: 638-644. 10.1111/j.1538-7836.2011.04222.x.CrossRefPubMed Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB: Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost. 2011, 9: 638-644. 10.1111/j.1538-7836.2011.04222.x.CrossRefPubMed
31.
go back to reference Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12: 1260-1268. 10.1101/gad.12.9.1260.PubMedCentralCrossRefPubMed Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12: 1260-1268. 10.1101/gad.12.9.1260.PubMedCentralCrossRefPubMed
32.
go back to reference Vik A, Mathiesen EB, Noto AT, Sveinbjornsson B, Brox J, Hansen JB: Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis. 2007, 191: 128-134. 10.1016/j.atherosclerosis.2006.03.002.CrossRefPubMed Vik A, Mathiesen EB, Noto AT, Sveinbjornsson B, Brox J, Hansen JB: Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis. 2007, 191: 128-134. 10.1016/j.atherosclerosis.2006.03.002.CrossRefPubMed
33.
go back to reference Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB: Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromso Study. J Thromb Haemost. 2010, 8: 2133-2139. 10.1111/j.1538-7836.2010.03990.x.CrossRefPubMed Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB: Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromso Study. J Thromb Haemost. 2010, 8: 2133-2139. 10.1111/j.1538-7836.2010.03990.x.CrossRefPubMed
34.
go back to reference Kozakova M, Muscelli E, Flyvbjerg A, Frystyk J, Morizzo C, Palombo C, Ferrannini E: Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab. 2008, 93: 2811-2818. 10.1210/jc.2007-2580.CrossRefPubMed Kozakova M, Muscelli E, Flyvbjerg A, Frystyk J, Morizzo C, Palombo C, Ferrannini E: Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab. 2008, 93: 2811-2818. 10.1210/jc.2007-2580.CrossRefPubMed
35.
go back to reference Gustafsson S, Lind L, Zethelius B, Venge P, Flyvbjerg A, Soderberg S, Ingelsson E: Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies. Eur J Endocrinol. 2010, 162: 543-550. 10.1530/EJE-09-1006.CrossRefPubMed Gustafsson S, Lind L, Zethelius B, Venge P, Flyvbjerg A, Soderberg S, Ingelsson E: Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies. Eur J Endocrinol. 2010, 162: 543-550. 10.1530/EJE-09-1006.CrossRefPubMed
36.
go back to reference Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005, 112: 1756-1762. 10.1161/CIRCULATIONAHA.104.530972.CrossRefPubMed Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005, 112: 1756-1762. 10.1161/CIRCULATIONAHA.104.530972.CrossRefPubMed
37.
go back to reference Cavusoglu E, Chopra V, Battala V, Ruwende C, Yanamadala S, Eng C, Pinsky DJ, Marmur JD: Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography. Am J Cardiol. 2008, 101: 1073-1078. 10.1016/j.amjcard.2007.12.008.CrossRefPubMed Cavusoglu E, Chopra V, Battala V, Ruwende C, Yanamadala S, Eng C, Pinsky DJ, Marmur JD: Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography. Am J Cardiol. 2008, 101: 1073-1078. 10.1016/j.amjcard.2007.12.008.CrossRefPubMed
38.
go back to reference McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, McMurray JJ: Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007, 28: 829-835. 10.1093/eurheartj/ehm033.CrossRefPubMed McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, McMurray JJ: Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007, 28: 829-835. 10.1093/eurheartj/ehm033.CrossRefPubMed
39.
go back to reference Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y: Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes. 2006, 55: 1954-1960. 10.2337/db05-1525.CrossRefPubMed Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y: Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes. 2006, 55: 1954-1960. 10.2337/db05-1525.CrossRefPubMed
Metadata
Title
Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men
Authors
Weena JY Chen
Luuk J Rijzewijk
Rutger W van der Meer
Martijn W Heymans
Eelco van Duinkerken
Mark Lubberink
Adriaan A Lammertsma
Hildo J Lamb
Albert de Roos
Johannes A Romijn
Jan WA Smit
Jeroen J Bax
Mette Bjerre
Jan Frystyk
Allan Flyvbjerg
Michaela Diamant
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2011
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-10-67

Other articles of this Issue 1/2011

Cardiovascular Diabetology 1/2011 Go to the issue